Overview

Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of BGM0504 Injection in Non-diabetic Overweight or Obese Adult Subjects

Status:
COMPLETED
Trial end date:
2025-03-03
Target enrollment:
Participant gender:
Summary
This is a Phase 1, double-blind, parallel-arm ,placebo-controlled study. The study will evaluate the pharmacokinetics (PK), pharmacodynamic (PD), safety and tolerability of BGM0504 following multiple subcutaneous (SC) administrations in non-diabetic overweight or obese adult subjects.
Phase:
PHASE1
Details
Lead Sponsor:
BrightGene Bio-Medical Technology Co., Ltd.